ERBB2 and breast carcinoma: When using an 18F-labeled HER2-targeting aptamer to conduct PET/CT imaging, Kim et al. (2019) demonstrated the ability of this molecule to facilitate cell surface HER2 recognition and to enable the preferential binding of HER2-positive breast cancer cells in vitro and in xenograft-bearing mice.